Non-viral Gene Therapy for Osteoarthritis

Frontiers in Bioengineering and Biotechnology

Ali Mobasheri¹  Eiva Bernotiene²  Ursule Kalvaityte²  Ilona Uzieliene² 

[1] Centre for Sport, Exercise and Osteoarthritis Versus Arthritis, Queen's Medical Centre, Nottingham, United Kingdom;Department of Regenerative Medicine, State Research Institute Centre for Innovative Medicine, Vilnius, Lithuania;Departments of Orthopedics, Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands;Research Unit of Medical Imaging, Physics and Technology, Faculty of Medicine, University of Oulu, Oulu, Finland;

关键词: osteoarthritis;    cartilage;    chondrocyte;    non-viral;    gene therapy;   

DOI  :  10.3389/fbioe.2020.618399

来源: DOAJ

【 摘 要 】

Strategies for delivering nucleic acids into damaged and diseased tissues have been divided into two major areas: viral and non-viral gene therapy. In this mini-review article we discuss the application of gene therapy for the treatment of osteoarthritis (OA), one of the most common forms of arthritis. We focus primarily on non-viral gene therapy and cell therapy. We briefly discuss the advantages and disadvantages of viral and non-viral gene therapy and review the nucleic acid transfer systems that have been used for gene delivery into articular chondrocytes in cartilage from the synovial joint. Although viral gene delivery has been more popular due to its reported efficiency, significant effort has gone into enhancing the transfection efficiency of non-viral delivery, making non-viral approaches promising tools for further application in basic, translational and clinical studies on OA. Non-viral gene delivery technologies have the potential to transform the future development of disease-modifying therapeutics for OA and related osteoarticular disorders. However, further research is needed to optimize transfection efficiency, longevity and duration of gene expression.

【 授权许可】

Unknown